Compare TSBK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | RIGL |
|---|---|---|
| Founded | 1915 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.8M | 628.4M |
| IPO Year | 1997 | 2000 |
| Metric | TSBK | RIGL |
|---|---|---|
| Price | $38.08 | $26.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 16.0K | ★ 353.2K |
| Earning Date | 04-28-2026 | 05-22-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | 21.93 | ★ 1867.68 |
| EPS | 1.04 | ★ 19.48 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | $36.64 | ★ $1.36 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $27.51 | $15.50 |
| 52 Week High | $40.41 | $52.24 |
| Indicator | TSBK | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 25.31 |
| Support Level | $37.56 | $18.14 |
| Resistance Level | $39.98 | $31.26 |
| Average True Range (ATR) | 0.84 | 1.55 |
| MACD | -0.12 | -0.43 |
| Stochastic Oscillator | 40.66 | 3.69 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.